Clinical Trial Update: PASCAL Laser Platform Produces Less Pain Responses Compared To Conventional Laser System [NA]

View source ↗

Summary

A completed clinical trial found that the PASCAL laser platform elicited fewer pain responses than a conventional laser system in diabetic retinopathy patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Retinopathy

Snippet

Sponsor: Kocatepe University | Conditions: Diabetic Retinopathy | NA | Status: COMPLETED